Abstract

The present proposal takes advantage of the wealth of clinical and basic investigative resources at the Dana-Farber Cancer Institute and its collaborative hospitals to develop an integrated program in both basic and clinical research. The principal goals of this program Project Grant are directed at the regulation of both leukemic and normal hematopoietic cell growth and differentiation and the development of novel immunotherapy, chemotherapy and transplantation treatment programs for adult and childhood leukemia and lymphoma. The basic studies include the following six proposals: A3) studies on the Regulation of Proliferation and Differentiation of Human Acute Myeloblastic Leukemic Cells (Griffin). A5) C-FmS and CSF-1 Gene Expression in Myeloid Differentiation and Leukemia (Kufe); A8) CD20, A B Lymphocyte-Specific Ion Channel That Regulates Proliferation and differentiation (Tedder); A9) Detection of Minimal Residual Lymphoid neoplasia by N-PCR (Sklar); A10) Regulation of the Gene for the Human Stem Cell Antigen CD34 in Normal and Leukemic Cells (Tenen); All) Novel Lymunotherapeutic Strategies (Schlossman and Breitmeyer). There are three major clinical research projects and they include; B2) Childhood Acute Lymphoblastic Leukemia (Sallan); B5) Multi-Disciplinary Strategies for the Treatment of Acute Myeloid Leukemia (Ritz); and B6) B Cell Non-Hodgkins Lymphoma; New Therapeutic Strategies (Nadler).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA034183-09
Application #
3093534
Study Section
Special Emphasis Panel (SRC (D1))
Project Start
1983-08-01
Project End
1994-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Lipshultz, Steven E; Alvarez, Jorge A; Scully, Rebecca E (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-33
Brown, Jennifer R; Feng, Yang; Gribben, John G et al. (2007) Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 13:1057-65
Barry, Elly; Alvarez, Jorge A; Scully, Rebecca E et al. (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8:1039-58
Scully, Rebecca E; Lipshultz, Steven E (2007) Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7:122-8
Alvarez, Jorge A; Scully, Rebecca E; Miller, Tracie L et al. (2007) Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 19:23-31
Lipshultz, Steven E; Wong, Julia C L; Lipsitz, Stuart R et al. (2006) Frequency of clinically unsuspected myocardial injury at a children's hospital. Am Heart J 151:916-22
Mone, Suzanne M; Gillman, Matthew W; Miller, Tracie L et al. (2004) Effects of environmental exposures on the cardiovascular system: prenatal period through adolescence. Pediatrics 113:1058-69
Lipshultz, Steven E; Somers, Michael J G; Lipsitz, Stuart R et al. (2003) Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 112:79-86
Grossbard, M L; Fidias, P; Kinsella, J et al. (1998) Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol 102:509-15
Nysom, K; Holm, K; Lipsitz, S R et al. (1998) Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 16:545-50

Showing the most recent 10 out of 272 publications